The venture builder or start-up studio model has gained prominence in nurturing early-stage biotech assets, offering a unique approach to supporting innovation. What distinguishes them from more traditional incubators and accelerators? Is there really a single start-up studio model? How do they collaborate with academic institutions, research organisations, and industry partners? How do venture builders effectively add value to early-stage biotech companies and has this proven effective? What are the challenges and limitations of the model?

Moderator: Gerald Law, Chief Executive, Innovation DB